Antibody-drug conjugates (ADCs) are linked by a tumor-targeting monoclonal antibodies (mAb) and cytotoxic payload drug through a chemical linker. The ADCs were originally designed to increase the effectiveness of chemotherapy and reduce its toxicity. Since the monoclonal antibody is recognized and combined cancer cell surface antigens, the cytotoxic molecules can be selectively "transported" directly into the tumor cells to exert an anti-cancer effect while avoiding effects on healthy cells. Researchers have found that the selection of monoclonal antibodies, small molecule drugs, and linkers is crucial to improve therapeutic qualities of ADCs. Targets for ADCs refer to antigens targeted monoclonal antibodies, and confirming these targets is the fist and key step of ADC development. Based on the data of ADCs in development and in the clinic and approved, CUSABIO collects and displays most targets for ADCs in the Figure 1.
Target antigens overexpressed in cancer cells
Target antigens regulated from
driver oncogenes
Target antigens in the tumor
vasculature and stroma
Figure 1. Target for ADCs in development and in the clinic and developed
The purity of human CD22 (Cat. No. CSB-MP004900HU) was more than 94% verified by SDS-PAGE.
The purity of human CD276 (Cat. No. CSB-MP733578HU) was more than 93% verified by SDS-PAGE.
The purity of human CD33 (Cat. No. CSB-MP004925HU) was more than 95% verified by SDS-PAGE.
The purity of human CD46 (Cat. No. CSB-MP004939HU) was more than 92% verified by SDS-PAGE.
Based on the SEQUEST from database of E.coli host and target protein, the LC-MS/MS Analysis result of Human CA9 (Cat. No. CSB-EP614990HUc0) could indicate that this peptide derived from E.coli-expressed Human CA9.
Based on the SEQUEST from database of E.coli host and target protein, the LC-MS/MS Analysis result of Human CASP3 (Cat. No. CSB-EP004548HU) could indicate that this peptide derived from E.coli-expressed Human CASP3.
Immobilized human CD48 (Cat. No. CSB-MP004941HU) at 2 μg/ml can bind Anti-CD48 rabbit monoclonal antibody, the EC50 of human CD48 protein is 0.5806-0.8463 ng/ml.
Immobilized human DLL3 (Cat. No. CSB-MP882142HU) at 2 μg/ml can bind Anti-DLL3 Recombinant Antibody (CSB-RA882142A1HU), the EC50 is 1.102-1.707 ng/mL.
Immobilized human ERBB2 (Cat. No. CSB-MP007763HU) at 2 μg/ml can bind Trastuzumab, the EC50 is 2.179-2.825 ng/ml.
Immobilized human MET (Cat. No. CSB-MP013714HU) at 2 μg/ml can bind Anti-MET recombinant antibody, the EC50 is 2.379-3.094 ng/ml.
Human EGF protein captured on COOH chip can bind Human EGFR protein, his and Myc tag (Cat. No. CSB-MP007479HU) with an affinity constant of 11.9nM as detected by LSPR Assay.
Human TNFSF13B protein Fc tag (CSB-MP897523HU1) captured on COOH chip can bind Human BCMA protein Fc tag (Cat. No. CSB-MP023974HU1) with an affinity constant of 39 nM as detected by LSPR Assay.
CUSABIO has developed a series of products with different species and tags for a variety of hot targets, which are suitable for immune, antibody screening, SPR, cell activity detection and other experiments. CUSABIO is committed to assisting you in drug development, and all activity test protocols are available for free. In addition, CUSABIO also provides related research antibodies and ELISA kits. If you don't find the targets you desired, you can leave message or chat to us by livechat.